Peptide ELISA: 1/1000. Western Blot: 2 - 4 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0,5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Wu, Roks, Leijten, Garrelds, Musterd-Bhaggoe, van den Bogaerdt, de Maat, Simoons, Danser, Oeseburg: "Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease." in: Clinical science (London, England : 1979), Vol. 126, Issue 6, pp. 441-9, (2014) (PubMed).
Bradykinin, a 9 aa peptide, is generated in pathophysiologic conditions such as inflammation, trauma, burns, shock, and allergy. Two types of G-protein coupled receptors have been found which bind bradykinin and mediate responses to these pathophysiologic conditions. The protein encoded by this gene is one of these receptors and is synthesized de novo following tissue injury. Receptor binding leads to an increase in the cytosolic calcium ion concentration, ultimately resulting in chronic and acute inflammatory responses. Bradykinin B1 receptor is generally only minimally expressed under normal physiological conditions, but the expression is induced rapidly under pathologic conditions such as ischemia, atheromatous disease, or exposure to inflammatory cytokines.Synonyms: B1 bradykinin receptor, B1R, BK-1 receptor, BKB1R, BKR1, BRADYB1, Bradykinin B1 Receptor